Teva Pharmaceuticals, a U.S. affiliate of Teva, announced the print publication of the IMPACT-TD Scale, a standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia, or TD, on different aspects of a patient’s daily functioning. IMPACT-TD categorizes the consequences of TD symptoms into multiple functional domains: social, psychological/psychiatric, physical and vocational/educational/recreational. The scale was developed to collect insights from not only patients but also family members, caregivers and providers, to help foster more productive dialogue and provide the most comprehensive understanding of the impact of TD.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEVA:
- Teva announces FDA approval of AUSTEDO XR tablets
- Teva Neuroscience granted FDA approval for amended Austedo XR NDA
- Axsome facing Auvelity IP challenge ‘not a surprise,’ says BofA
- Axsome received Paragraph IV certification notice on Auvelity ANDA from Teva
- Teva settles price-fixing claims in Florida for $6.73M